Real-World Effectiveness And Safety of Teduglutide in Adult Short Bowel Syndrome: A Meta-analysis

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Evolution of Regulatory Frameworks for Real-World Data

The pharmaceutical landscape has undergone a profound transformation as...

The Way Forward for the Healthcare Data Ecosystem

The transformation of worldwide healthcare by way of digital...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Randomized clinical trials have demonstrated that teduglutide, a glucagon-like peptide-2 (GLP-2) analog, improves intestinal absorption in patients with short bowel syndrome (SBS) with parenteral support (PS) dependence.1 Our objective was to assess real-world evidence of teduglutide effectiveness and safety in adult SBS patients with PS dependence in a real-world setting.

Methods
We searched PubMed databases for English language papers published through January 22, 2020. We completed a systematic literature review (SLR) to identify manuscripts (n=162) describing real-world evidence studies of teduglutide in adult SBS patients with PS dependence. Random effects meta-analysis of data identified in the SLR generated summary estimates, using the DerSimonian-Laird approach,2 for mean change in PS volume, mean change in PS infusion frequency, and percent of responders (≥20% PS volume reduction from baseline) by weeks 24 and 48 or end of follow-up (EOF). We also analyzed reported adverse event (AE) data. We present efficacy results as combined point estimates.

Results
Seven studies involving 127 participants were included that investigated teduglutide. By week 24, PS volume changed by a combined point estimate (CPE) [95% CI] of –4.71 [–6.63, –2.79] L/wk and PS frequency changed by a CPE [95% CI] of –1.87 [–3.22, –0.52] days/wk. By week 48 or EOF, PS volume changed by a CPE [95% CI] of –5.41 [–6.53, –4.30] L/wk (Figure 1) and PS frequency changed by a CPE [95% CI] of –2.32 [–3.55, –1.09] days/wk. A CPE of approximately 70%-80% of patients responded (achieved ≥20% reduction in PS) to teduglutide by 24 or 48 weeks or EOF (week 48/EOF in Figure 2). AEs reported in 5 of 7 studies included abdominal pain (14.3%-50.0%), nausea/vomiting (7.7%-33.3%), catheter sepsis (16.7%-30.8%), and stoma enlargement in 50%-100% of patients with stomas. Four deaths were reported in 3 of 7 studies (none were associated with teduglutide per authors).

Conclusions
Although it is difficult to compare data from different settings, this meta-analysis of real-world data shows teduglutide efficacy was equal to or greater than that in randomized clinical trials for adults with SBS with PS dependence. Safety data appear comparable. Further research is needed on modifiable factors associated with best patient outcomes with teduglutide.

References
1. Jeppesen PB, Pertkiewicz M, Messing B, et al. Gastroenterology. 2012;143(6):1473-1481.e3.
2. DerSimonian R, Laird N. Control Clin Trials. 1986;7(3):177-188.

 

Latest stories

Related stories

Evolution of Regulatory Frameworks for Real-World Data

The pharmaceutical landscape has undergone a profound transformation as...

The Way Forward for the Healthcare Data Ecosystem

The transformation of worldwide healthcare by way of digital...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back